Ozoralizumab

• CAT Number: I041548
• CAS Number: 1167985-17-2
• Purity: ≥95%

Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1].
Ozoralizumab (ATN-103; 0-1000 pM; 48 h) has high TNFα-neutralizing potency in the L929 cell cytotoxicity assay with KD values of 20.2 pM and 16.1 pM for human TNFα and monkey TNFα, respectively[1].
Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores[1].

Reference

[1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008.
 [Content Brief]